Adma Biologics ADMA Institutional Ownership

Updated Oct 11, 2026

Adma Biologics, Inc. (NASDAQ:ADMA) was reported as a holding by 324 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 89.04% of outstanding shares in Q2 2026, down from 89.74% the quarter before.
• Total shares held in Adma Biologics fell 4.08% from Q1 2026, while the number of holders fell 11.96% from Q2 2025.
• Of the 324 holders of ADMA in Q2 2026, 143 added to their positions, 148 reduced their stakes and 33 left their positions unchanged.
• Institutional investors held 203.21Mn shares of Adma Biologics in total at the end of Q2 2026, down 8.64Mn from the prior quarter and down 5.95Mn from a year earlier.
• BlackRock, Inc. was the top holder of Adma Biologics as of June 30, 2026, with 38.36Mn shares, or 16.81% of shares outstanding.
• The biggest increases in ADMA positions during Q2 2026 came from Rubric Capital Management LP (+7.53Mn shares), First Trust Advisors LP (+7.44Mn shares), D. E. Shaw & Co., Inc. (+4.71Mn shares), State Street Corp (+3.03Mn shares) and BlackRock, Inc. (+1.52Mn shares).
• Holders that trimmed the most shares of Adma Biologics in Q2 2026 while keeping a position were American Century Companies Inc (-4.56Mn shares), Citadel Advisors LLC (-4.44Mn shares), Invesco Ltd. (-3.58Mn shares), Point72 Asset Management, L.P. (-2.87Mn shares) and Nuveen, LLC (-2.84Mn shares).
• Per Business Quant data, the 10 largest holders of Adma Biologics at the end of Q2 2026 were BlackRock, Inc. (38.36Mn shares), State Street Corp (17.12Mn shares), Vanguard Capital Management LLC (10.1Mn shares), Vanguard Portfolio Management LLC (10.09Mn shares), Rubric Capital Management LP (9.34Mn shares), Capital Research Global Investors (8.76Mn shares), First Trust Advisors LP (7.8Mn shares), Geode Capital Management, LLC (6.06Mn shares), Caligan Partners LP (5.73Mn shares) and D. E. Shaw & Co., Inc. (5.27Mn shares).